المؤلفون: Rasool, Reyaz ur, O’Connor, Caitlin M., Das, Chandan Kanta, Alhusayan, Mohammed, Verma, Brijesh Kumar, Islam, Sehbanul, Frohner, Ingrid E., Deng, Qu, Mitchell-Velasquez, Erick, Sangodkar, Jaya, Ahmed, Aqila, Linauer, Sarah, Mudrak, Ingrid, Rainey, Jessica, Zawacki, Kaitlin P., Suhan, Tahra K., Callahan, Catherine G., Rebernick, Ryan, Natesan, Ramakrishnan, Siddiqui, Javed, Sauter, Guido, Thomas, Dafydd, Wang, Shaomeng, Taylor, Derek J., Simon, Ronald, Cieslik, Marcin, Chinnaiyan, Arul M., Busino, Luca, Ogris, Egon, Narla, Goutham, Asangani, Irfan A.

المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

الاتاحة: http://dx.doi.org/10.1038/s41467-023-40760-6
https://www.nature.com/articles/s41467-023-40760-6.pdf
https://www.nature.com/articles/s41467-023-40760-6

المؤلفون: Ahmed, Aqila A., Strong, Michael J., Zhou, Xiaofeng, Robinson, Tyler, Rocco, Sabrina, Siegel, Geoffrey W., Clines, Gregory A., Moore, Bethany B., Keller, Evan T., Szerlip, Nicholas J.

المساهمون: Quaini, Federico, National Institutes of Health, Rogel Cancer Center, U.S. Department of Defense, U.S. Department of Veterans Affairs, Society of Neurological Surgeons

المصدر: PLOS ONE ; volume 17, issue 4, page e0267642 ; ISSN 1932-6203

الاتاحة: http://dx.doi.org/10.1371/journal.pone.0267642
https://dx.plos.org/10.1371/journal.pone.0267642

المؤلفون: Schnepp, Patricia M., Ahmed, Aqila, Escara-Wilke, June, Dai, Jinlu, Shelley, Greg, Keller, Jill, Mizokami, Atsushi, Keller, Evan T.

المصدر: BMC Cancer ; volume 21, issue 1 ; ISSN 1471-2407

الاتاحة: http://dx.doi.org/10.1186/s12885-021-09048-0
https://link.springer.com/content/pdf/10.1186/s12885-021-09048-0.pdf
https://link.springer.com/article/10.1186/s12885-021-09048-0/fulltext.html

المؤلفون: Strong, Michael, Ahmed, Aqila, Calinescu, Anda-Alexandra, Zhou, Xiaofeng, Robinson, Tyler, Rocco, Sabrina, Siegel, Geoffrey, Clines, Gregory, Moore, Bethany, Keller, Evan, Szerlip, Nicholas

المصدر: Neuro-Oncology ; volume 22, issue Supplement_2, page ii105-ii106 ; ISSN 1522-8517 1523-5866

مصطلحات موضوعية: Cancer Research, Neurology (clinical), Oncology

الاتاحة: http://dx.doi.org/10.1093/neuonc/noaa215.437
http://academic.oup.com/neuro-oncology/article-pdf/22/Supplement_2/ii105/34690903/noaa215.437.pdf

المؤلفون: Schnepp, Patricia M., Ahmed, Aqila, Escara-Wilke, June, Dai, Jinlu, Shelley, Greg, Keller, Jill, Mizokami, Atsushi, Keller, Evan T.

مصطلحات موضوعية: organic chemicals, urologic and male genital diseases, neoplasms

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae7bb4bec42d54af619a20968de7a73

المؤلفون: Ma, Hongzhi, Wu, Yizhen, Simon, Kirk, Ahmed, Aqila, Cabelof, Diane C

المصدر: The FASEB Journal ; volume 27, issue S1 ; ISSN 0892-6638 1530-6860

الاتاحة: http://dx.doi.org/10.1096/fasebj.27.1_supplement.1077.13

المؤلفون: Ahmed, Aqila A., Robinson, Tyler, Palande, Monica, Escara‐wilke, June, Dai, Jinlu, Keller, Evan T.

مصطلحات موضوعية: DNA damage response, Notch signaling, Notch1, prostate cancer, hormone sensitivity, Genetics, Molecular, Cellular and Developmental Biology, Science, Health Sciences

وصف الملف: application/pdf

Relation: Ahmed, Aqila A.; Robinson, Tyler; Palande, Monica; Escara‐wilke, June; Dai, Jinlu; Keller, Evan T. (2019). "Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression." Journal of Cellular Biochemistry 120(10): 16946-16955.; https://hdl.handle.net/2027.42/151373; Journal of Cellular Biochemistry; Deng G, Ma L, Meng Q, et al. Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology. J Cancer Res Clin Oncol. 2016; 142 ( 3 ): 531 - 547. https://doi.org/10.1007/s00432-015-1946-x; Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET. Notch pathway inhibition using PF-03084014, a gamma-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin Cancer Res. 2015; 21 ( 20 ): 4619 - 4629. https://doi.org/10.1158/1078-0432.CCR-15-0242; Carvalho FL, Simons BW, Eberhart CG, Berman DM. Notch signaling in prostate cancer: a moving target. Prostate. 2014; 74 ( 9 ): 933 - 945. https://doi.org/10.1002/pros.22811; Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE. In vitro model systems to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer. 2013; 20 ( 2 ): R49 - R64. https://doi.org/10.1530/erc-12-0401; Yu S-Q, Lai K-P, Xia S-J, Chang H-C, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl. 2009; 11 ( 1 ): 39 - 48. https://doi.org/10.1038/aja.2008.44; Korenchuk S, Lehr JE, L MC, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001; 15 ( 2 ): 163 - 168.; Litvinov Ivan V, Vander Griend Donald J, Xu Yi, Antony Lizamma, Dalrymple Susan L, Isaacs John T. Low-Calcium Serum-Free Defined Medium Selects for Growth of Normal Prostatic Epithelial Stem Cells. Cancer Research. 2006; 66 ( 17 ): 8598 - 8607. https://doi.org/10.1158/0008-5472.can-06-1228; Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 2001; 61 ( 19 ): 7291 - 7297.; Zayzafoon Majd, Abdulkadir Sarki A, McDonald Jay M. Notch Signaling and ERK Activation Are Important for the Osteomimetic Properties of Prostate Cancer Bone Metastatic Cell Lines. Journal of Biological Chemistry. 2003; 279 ( 5 ): 3662 - 3670. https://doi.org/10.1074/jbc.m308158200; Patrawala Lubna, Calhoun Tammy, Schneider-Broussard Robin, Zhou Jianjun, Claypool Kent, Tang Dean G. Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+and ABCG2-Cancer Cells Are Similarly Tumorigenic. Cancer Research. 2005; 65 ( 14 ): 6207 - 6219. https://doi.org/10.1158/0008-5472.can-05-0592; Mohamed AA, Tan SH, Xavier CP, et al. Synergistic activity with NOTCH inhibition and androgen ablation in ERG-positive prostate cancer cells. Mol Cancer Res. 2017; 15 ( 10 ): 1308 - 1317. https://doi.org/10.1158/1541-7786.MCR-17-0058; Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993; 23 ( 2 ): 123 - 134.; Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle. 2012; 11 ( 24 ): 4579 - 4588. https://doi.org/10.4161/cc.22852; Huang Q, Raya A, DeJesus P, et al. Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci USA. 2004; 101 ( 10 ): 3456 - 3461.; Vermezovic J, Adamowicz M, Santarpia L, et al. Notch is a direct negative regulator of the DNA-damage response. Nat Struct Mol Biol. 2015; 22 ( 5 ): 417 - 424. https://doi.org/10.1038/nsmb.3013; Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genet. 2010; 42 ( 8 ): 668 - 675. https://doi.org/10.1038/ng.613; Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation. 2008; 76 ( 6 ): 699 - 716. https://doi.org/10.1111/j.1432-0436.2008.00288.x; Thompson TC, Li L. Connecting androgen receptor signaling and the DNA damage response: development of new therapies for advanced prostate cancer. Mol Cel Oncol. 2017; 4 ( 4 ): e1321167 - e1321167. https://doi.org/10.1080/23723556.2017.1321167; Chatterjee P, Choudhary GS, Alswillah T, et al. The TMPRSS2-ERG gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition. Mol Cancer Ther. 2015; 14 ( 8 ): 1896 - 1906. https://doi.org/10.1158/1535-7163.MCT-14-0865; Lin RW, Ho CJ, Chen HW, et al. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. Cell Cycle. 2018; 17 ( 17 ): 2175 - 2186. https://doi.org/10.1080/15384101.2018.1520565; Qiu S, Deng L, Bao Y, et al. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition. Anticancer Drugs. 2018; 29 ( 9 ): 871 - 879. https://doi.org/10.1097/CAD.0000000000000659; Zhang L, Sha J, Yang G, Huang X, Bo J, Huang Y. Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells. Cell Cycle. 2017; 16 ( 10 ): 999 - 1007. https://doi.org/10.1080/15384101.2017.1312237; Carvalho FL, Marchionni L, Gupta A, et al. HES6 promotes prostate cancer aggressiveness independently of Notch signaling. J Cell Mol Med. 2015; 19 ( 7 ): 1624 - 1636. https://doi.org/10.1111/jcmm.12537; Chanrion M, Kuperstein I, Barrière C, et al. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nat Commun. 2014; 5: 5005. https://doi.org/10.1038/ncomms6005 https://www.nature.com/articles/ncomms6005#supplementary-information; Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B, Bevan CL. Repression of androgen receptor activity by HEYL, a third member of the Hairy/enhancer-of-split-related family of Notch effectors. J Biol Chem. 2011; 286 ( 20 ): 17796 - 17808. https://doi.org/10.1074/jbc.M110.198655; Kron Ken J, Murison Alexander, Zhou Stanley, Huang Vincent, Yamaguchi Takafumi N, Shiah Yu-Jia, Fraser Michael, van der Kwast Theodorus, Boutros Paul C, Bristow Robert G, Lupien Mathieu. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics. 2017; 49 ( 9 ): 1336 - 1345. https://doi.org/10.1038/ng.3930; Cui J, Wang Y, Dong B, et al. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. Int J Cancer. 2018; 143 ( 3 ): 645 - 656. https://doi.org/10.1002/ijc.31346; Su Q, Xin L. Notch signaling in prostate cancer: refining a therapeutic opportunity. Histol Histopathol. 2016; 31 ( 2 ): 149 - 157. https://doi.org/10.14670/HH-11-685; Bertrand FE, McCubrey JA, Angus CW, Nutter JM, Sigounas G. NOTCH and PTEN in prostate cancer. Adv Biol Regul. 2014; 56: 51 - 65. https://doi.org/10.1016/j.jbior.2014.05.002; Yu Y, Zhang Y, Guan W, et al. Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. Mol Cancer Res. 2014; 12 ( 6 ): 830 - 842. https://doi.org/10.1158/1541-7786.mcr-13-0545; Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey1, a mediator of Notch signaling, is an androgen receptor corepressor. Mol Cell Biol. 2005; 25 ( 4 ): 1425 - 1436. https://doi.org/10.1128/MCB.25.4.1425-1436.2005

الاتاحة: https://hdl.handle.net/2027.42/151373
https://doi.org/10.1002/jcb.28954

المؤلفون: Ahmed, Aqila A., Smoczer, Cristine, Pace, Brianna, Patterson, David, Cabelof, Diane Cress

المصدر: Knoebel Institute for Healthy Aging: Faculty Scholarship

مصطلحات موضوعية: Aging, DNA polymerase beta, Senescence, DNA repair, Knoebel Institute for Healthy Aging, Medicine and Health Sciences

Relation: https://digitalcommons.du.edu/knoebel_fac/11

الاتاحة: https://digitalcommons.du.edu/knoebel_fac/11